Search
Thymidine
go.drugbank.com/drugs/DB04485ApprovedInvestigational[A274683, A274688] As of now, its primary role is in research and as a sensitizer or modulator in experimental chemotherapy regimens, rather than a standalone, approved therapeutic agent. … Thymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis.
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigationalin which the patient develops an infection during a period of significant neutropenia. … [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer
Butamben
go.drugbank.com/drugs/DB11148ApprovedWithdrawn[A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics. … Butamben is a local anesthetic in the form of n-butyl-p-aminobenzoate.
Disulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalA carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. … It acts by inhibiting aldehyde dehydrogenase.
Categories: Drugs Used in Alcohol Dependence, Drugs Used in Addictive DisordersUrokinase-type plasminogen activator
go.drugbank.com/bio_entities/BE0000895TargetEnzymeHumansSecreted as an inactive zymogen, it is recruited and activated at the cell surface through interaction with the urokinase plasminogen activator receptor (uPAR).
Synonyms: uPAFunction: receptor ligand activityAC-100
go.drugbank.com/drugs/DB05671InvestigationalAC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). … It is being developed by Acologix, Inc.
Diethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalIt is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290) … A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category.
Berotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798] … Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE).
Categories: Drugs Used in Hereditary AngioedemaImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalImatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. … The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient.
Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawnEflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. … [A262823,L49318] Subsequently, on December 14, 2023, the FDA approved eflornithine again but under the brand name IWILFIN as an oral maintenance therapy to reduce the risk of relapse in adult and pediatric